Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07013643 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
A Phase 1 study of Healthy Participants, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 2
- Study locations
NCT07013643 is a Phase 1 study of Healthy Participants that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 75 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (15% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT07013643, a Phase 1 study of Healthy Participants, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will measure the effects of multiple doses of AZD6234, AZD9550 and a combination of AZD9550 and AZD6234 given as injection(s) on pharmacokinetics (PK) of combined oral contraceptive (CoC) ethinyl estradiol (EE)/levonorgestrel (LEVO) in healthy female participants with obesity.
Conditions Studied
Interventions
- DRUG AZD6234
- DRUG Ethinyl estradiol/Levonorgestrel (EE/LEVO)
- DRUG Acetaminophen (APAP)
- DRUG AZD9550
Study Locations (2)
California
- Research Site - Glendale
Maryland
- Research Site - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-06-04 |
| Est. Completion | 2026-12-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07013643
The ClinicalTrials.gov registry entry for NCT07013643 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (15% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 4 interventions - of which AZD6234 is the first listed.
NCT07013643 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Maryland.
Frequently Asked Questions
What is clinical trial NCT07013643 about?
NCT07013643 is a clinical study titled "A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity". This study will measure the effects of multiple doses of AZD6234, AZD9550 and a combination of AZD9550 and AZD6234 given as injection(s) on pharmacokinetics (PK) of combined oral contraceptive (CoC) ethinyl estradiol (EE)/levonorgestrel (LEVO) in healthy female participants with obesity.
What is the current status of trial NCT07013643?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2025-06-04. Estimated completion is 2026-12-25.
What conditions does trial NCT07013643 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT07013643?
The interventions under investigation include: AZD6234 (DRUG), Ethinyl estradiol/Levonorgestrel (EE/LEVO) (DRUG), Acetaminophen (APAP) (DRUG), AZD9550 (DRUG).
Who is sponsoring clinical trial NCT07013643?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07013643 being conducted?
This trial has 2 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.